ArticleNPJ breast cancer2026

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.

Marcin Kubeczko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.